Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bococizumab + recombinant human hyaluronidase
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
This is a combination of **bococizumab**, a humanized monoclonal antibody that targets **proprotein convertase subtilisin/kexin type 9 (PCSK9)**, and **recombinant human hyaluronidase (rHuPH20)**, an enzyme enhancing subcutaneous (SC) absorption and dispersion of co-administered therapeutics. Bococizumab inhibits PCSK9, leading to increased LDL receptor levels and thus lowering LDL-cholesterol. rHuPH20 hydrolyzes hyaluronan in the extracellular matrix, temporarily increasing SC tissue permeability and facilitating delivery of larger volumes or concentrations of injected drugs. The combination was investigated to allow less frequent dosing and improved bioavailability of bococizumab. The clinical development of bococizumab was discontinued, and the combination did not demonstrate a proportional increase in lipid-lowering efficacy, despite increased bioavailability.
- Other names
- bococizumab co-mixed with recombinant human hyaluronidasebococizumab + rHuPH20
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on bococizumab + recombinant human hyaluronidase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bococizumab + recombinant human hyaluronidase.